News >

Adjuvant Ipilimumab Shows Early Activity in Advanced Cervical Cancer

Nichole Tucker
Published: Thursday, Feb 20, 2020

Jyoti S. Mayadev, MD, associate professor of Radiation Medicine and Applied Sciences, director of Gynecologic Brachytherapy and chief of Gynecology Oncology Radiation Services at University of California, San Diego Health

Jyoti S. Mayadev, MD

Immune checkpoint blockade with ipilimumab (Yervoy), combined with radiation therapy, is tolerable and effective in patients with node-positive, stage Ib2 to IVA cervical cancer, according to results of a prospective phase I study.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication